International Journal for Scientific Researches in Ayurveda (IJSRA): An International Bimonthly Journal by Maharshi Charaka Ayurveda Organization (Regd) for Scientific Researches in Ayurveda, is published bimonthly by Charaka Publishing House, Vijayapur (Karnataka). The full text of this journal is accessible on website www.ijsra.com

The ‘IJSRA’ Journal aims to publish the scientific and research outcomes of Ayurveda with a view to inform and share review of scientific findings, advice, risk assessment conclusions and recommendations for further research in the areas within the limits of Ayurveda. It also aims to increase the visibility and awareness of Ayurvedic scientific work worldwide. The journal allows free access(open access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. 


This journal is devoted to the publication of Research Articles / Review Articles / Case Reports on the utilization of knowledge of Ayurveda and other traditional systems of medicines. The spectrum of coverage is broad, encompassing all eight divisions of Ayurveda including clinical researches in Kayachikitsa (General medicine), Shalya Tantra (Surgery), Shalakya Tantra (ENT & Ophthalmology), Stri Roga Prasuti Tantra (Gynecology & Obstetrics), Kaumar Bhritya (Pediatrics); Drug researches in Dravyaguna (Pharmacology), Rasa Shastra & Bhaishajya Kalpana (Ayurvedic Pharmaceuticles), Literary Researches in Maulika Siddhanta & Samhita (Basic Principles) along with History, Descriptions of herbal remedies, useful for the treatment of human aliments etc. It also deals with clinical and pharmacological evaluation of herbs, minerals, metals  and animal products, validation of food remedies, phytochemistry, ethnomedicine, survey of medicinal plants, nutraceuticals, drug standardization, biotechnology, agriculture, horticulture, pharmacovigilance etc. relating to medicinal plants.

IJSRA also accepts standard review articles based on AYUSH, newly introduced diseases with their updated scientific knowledge in contemporary sciences. The guidelines can also be downloaded from website (http://www.ijsra.com).


The journal allows free access (open access) to its contents and will be indexed with Directory of Open Access Journals (DOAJ), Open Access Initiative, Worldcat, Index Copernicus, Google Scholar, Open Access Digital Library, Jour Info,  AYUSH Portal, Academic Journals Database, Researchbib, Geneva Foundation for Medical Education and Research, Ottawa University, Lupton University Library, UCSF Library and Center for Knowledge Management, J-Gate, NECKER, Ulrich, Electronic Journal Libray (ZDB), One Search : Lancaster University Library, Virtual Science Library, Dukes University Library, Boston University Libraries, ProQuest, DRJI etc.


All submitted manuscripts are read by the editorial staff. To save time for authors and peer-reviewers, only those papers that seem most likely to meet our editorial criteria are sent for double blind review. Those papers judged by the editors to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review (although these decisions may be based on informal advice from specialists in the field).

Manuscripts judged to be of potential interest to our readership are sent for double blind review, typically to two or three reviewers, but sometimes more if special advice is needed (for example on statistics or a particular technique). The editors then make a decision based on the reviewers' advice, from among several possibilities:

  • Accept, with or without editorial revisions.

  • Invite the authors to revise their manuscript to address specific concerns before a final decision is reached

  • Reject, but indicate to the authors that further work might justify a resubmission.

  • Reject outright, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems

Reviewers are welcome to recommend a particular course of action, but they should bear in mind that the other reviewers of a particular paper may have different technical expertise and/or views, and the editors may have to make a decision based on conflicting advice. The most useful reports, therefore, provide the editors with the information on which a decision should be based. Setting out the arguments for and against publication is often more helpful to the editors than a direct recommendation one way or the other.

Editorial decisions are not a matter of counting votes or numerical rank assessments, and we do not always follow the majority recommendation. We try to evaluate the strength of the arguments raised by each reviewer and by the authors, and we may also consider other information not available to either party. Our primary responsibilities are to our readers and to the scientific community at large, and in deciding how best to serve them, we must weigh the claims of each paper against the many others also under consideration.

We may return to reviewers for further advice, particularly in cases where they disagree with each other, or where the authors believe they have been misunderstood on points of fact. We therefore ask that reviewers should be willing to provide follow-up advice as requested. We are very aware, however, that reviewers are usually reluctant to be drawn into prolonged disputes, so we try to keep consultation to the minimum we judge necessary to provide a fair hearing for the authors.

When reviewers agree to assess a paper, we consider this a commitment to review subsequent revisions. However, editors will not send a resubmitted paper back to the reviewers if it seems that the authors have not made a serious attempt to address the criticisms.

We take reviewers' criticisms seriously; in particular, we are very reluctant to disregard technical criticisms. In cases where one reviewer alone opposes publication, we may consult the other reviewers as to whether s/he is applying an unduly critical standard. We occasionally bring in additional reviewers to resolve disputes, but we prefer to avoid doing so unless there is a specific issue, for example a specialist technical point, on which we feel a need for further advice.


Authors are asked to write their manuscripts in English using an easily readable style. Ayurvedic terms and other Latin terms must be Italized and its equivalent english terminology should be mentioned in first instance in a bracket, for example: Urdhwaga Amlapitta (Non ulcer dyspepsia). Spelling and phraseology should conform to standard English usage and should be consistent throughout the paper. A manuscript will be considered for publication on the understanding that:

  1. All named authors have agreed to its submission.

  2. It is not currently being considered for publication by another journal.

  3. If the paper is accepted it will not subsequently be published in the same or similar form in any language without the consent of publishers.

  4. Authors have obtained permission from their employers or institution to publish, if they have a contractual or moral obligation to do so.

Authors will be entitled to publish any part of their paper elsewhere without permission, provided the usual acknowledgements are given. The assignment of copyright will not affect subsisting patent rights and arrangements relating to them.

Original Research Articles should include, as appropriate:

  1. A clear statement of purpose;

  2. A historical review when desirable;

  3. A description of the procedures, methods, and subjects or materials used (previously published procedures require only references to the original).

  4. A full report of the findings, including discussion and references to relevant findings of other researchers.


Article Type


Original Article

These should follow the structure outlined below

Review Article

Updates on progress in the main field of Ayurvedic Basic Principles, Tridosha Siddhanta, Panchamahabhuta, Pharmacokinetics, Pharmacodynamics of Ayurvedic drugs, Ayurvedic drug delievery system etc.

Short Communications

Shorter descriptions of important innovative developments will be considered for preliminary publication. These should consist of two pages of text, one figure or table and up to 10 references

Case Studies

Short descriptions using several well documented case studies will be considered for preliminary publication. These should consists of 2 pages of text, figures and tables and upto 10 references.

Letters to the Editor

Brief comments on articles published in the journal or other information of interest to our readers


  1. Title page (excluding acknowledgements)
  2. Abstract
  3. Introduction
  4. Materials (or patients) and methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Conflict of Interest
  9. References
  10. Tables
  11. Figures

Title page

The title page should bear the title of the paper, the full names of all the authors, highest academic degree obtained, and their affiliations, together with the name, full postal address, telephone and fax numbers and e-mail address of the author to whom correspondence and offprint requests are to be sent (This information is also asked for on the electronic submission form). The title should be brief, informative, of 150 characters or less and should not make a statement or conclusion. The running title should consist of not more than 50 letters and spaces. It should be as brief as possible, convey the essential message of the paper and contain no abbreviations. Authors should disclose the sources of any support for the work, received in the form of grants and/or equipment and drugs.


The abstract should not exceed 200 words.


The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible but can include a short historical review where ever desirable.

Materials and Methods

This section should contain sufficient detail, so that all experimental procedures can be reproduced, and include references. Methods, however, that have been published in detail elsewhere should not be described in detail. Authors should provide the name of the manufacturer and their location for any specifically named medical equipment and instruments, and all drugs should be identified by their pharmaceutical names, and by their trade name if relevant.

Results and Discussion

The Results section should briefly present the experimental data in text, tables or figures. Tables and figures should not be described extensively in the text, either. The discussion should focus on the interpretation and the significance of the findings with concise objective comments that describe their relation to other work in the area. It should not repeat information in the results. The final paragraph should highlight the main conclusion(s), and provide some indication of the direction future research should take.


These should be brief, and should include sources of support including sponsorship (e.g. university, charity, commercial organization) and sources of material (e.g. novel drugs) not available commercially.

Conflict of interest

Authors must declare whether or not there is any competing financial interests in relation to the work described. This information must be included at this stage and will be published as part of the paper. Conflict of interest should also be noted on the supplementary covering letter and as part of the submission process.


Only papers directly related to the article should be cited. Exhaustive lists should be avoided. References should follow the Vancouver format. In the text they should appear as numbers starting at one and at the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six only should be quoted, followed by et al. Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such. Papers in press and papers already submitted for publication may be included in the list of references but no citation is required for work that is not yet submitted for publication.

Journal article, up to six authors:

Rutanen J, Turunen A-M, Teittinen M, Rissanen TT, Heikura T, Koponen JK et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther2005; 12: 980–987.

Journal article, e-pub ahead of print:

Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C et al. In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther; e-pub ahead of print 14 March 2008; doi:10.1038/cgt.2008.12

Journal article, in press:

Wang R, Lin F, Wang X, Gao P, Dong K, Zou A-M et al. Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther (in press).

Complete book:

Gordon MY, Barre AJ. Bone Marrow Disorder: the Biological Basis of Clinical Problems. Blackwell Scientific Publishers: Oxford, 1985.

Chapter in book:

Meyerowitz BE, Heinrich RI, Schag CC. A competency-based approach to coping with cancer. In: Burish TG, Bradley L (eds). Coping With Chronic Illness: Research and Applications, 2nd edn. Academic Press: New York, 1983, pp 137–158.


Feig SA, Lenarsky C, Moss T, Gallardo RL, Juneja HS, Gordon MY et al. Bone marrow transplantation for neuroblastoma. Exp Hematol 1985; 13(Suppl 2): 362 (abstract 102).


Kyritsis AP, Rao JS, Puduvalli VK. Radio-responsive TRAIL gene therapy for malignant gliomas [letter].Cancer Gene Ther 2007; 14: 1002.


These should be labelled sequentially and cited within the text. Each table should be presented on its own page, numbered and titled. Reference to table footnotes should be made by means of Arabic numerals. Tables should not duplicate the content of the text. They should consist of at least two columns; columns should always have headings. Authors should ensure that the data in the tables are consistent with those cited in the relevant places in the text, totals add up correctly, and percentages have been calculated correctly. Unlike figures or images, tables may be embedded into the word processing software if necessary, or supplied as separate electronic files.


Figures and images should be labelled sequentially, numbered and cited in the text. Figure legends should be brief, specific and appear on a separate manuscript page after the References section. Refer to (and cite) figures specifically in the text of the paper. Figures should not be embedded within the text. If a table or figure has been published before, the authors must obtain written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. This follows for quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote. Scale markers should be used in the image for electron micrographs, and indicate the type of stain used.

Manuscript status

After your manuscript is approved, you will receive an email acknowledgement. You can check the manuscript’s status at any time in the review process by: 

  1. Accessing the system with your password or via the link provided in the acknowledgement email

  2. Clicking on the link represented by your manuscript tracking number and abbreviated title on your homepage.

  3. Clicking on the "Check Status" link at the bottom of the displayed page.

This procedure will display tracking information about where your manuscript is in the submission/peer review process. See Navigating the system in the Submission of Papers section for more information.

Copyright Agreement

Once a manuscript is accepted, the corresponding author must complete and sign the "Copyright Agreement" form and return it to the editorial office. Failure to promptly return the form will result in delays of your paper’s publication. A copy of the Licence to Publish form can be found at http://www.ijsra.com/Copyright.doc